• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
【24h】

Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.

机译：FOLFIRI-贝伐单抗用于大肠肝转移的术前化疗后门静脉血栓形成和脂肪变性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In order to discuss the role of preoperative chemotherapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with lobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapy-induced liver injury.
机译：为了讨论术前化学疗法对大肠肝转移的作用（在肝切除术之前经常使用，即使在有可切除疾病的患者中也很常见），我们在此报告两种并发症的发展，部分门静脉血栓形成和肝小叶变性伴小叶性炎症，在术前用FOLFIRI加贝伐珠单抗进行大肠肝转移化疗的过程中，这一认识导致及时停止化疗，并改变了通过先进技术切除肿瘤和受损肝脏的手术策略。我们得出结论，治疗的持续时间以及药物剂量和组合可能会影响化学疗法诱发的肝损伤的发展。外科医生和肿瘤内科医生必须共同努力，为患有多种结直肠肝转移的患者设计安全，合理和符合肿瘤学的治疗方法，并增进对化学疗法诱发的肝损伤发病机制的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号